The pharmacokinetics of rituximab following an intravitreal injection

Experimental Eye Research

Volumn 82, Issue 5, 2006, Pages 760-766

  Kim, Hyuncheol ^a   Csaky, Karl G ^a   Chan, Chi Chao ^a   Bungay, Peter M ^b   Lutz, Robert J ^b   Dedrick, Robert L ^b   Yuan, Peng ^b   Rosenberg, Jay ^c   Grillo Lopez, Antonio J ^c,e   Wilson, Wyndham H ^d   Robinson, Michael R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BIOGEN   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Neoplastic and Autoimmune Diseases Research Institute   (United States)

Author keywords

B cell lymphoma; Intravitreal injection; Pharmacokinetic analysis; Rituximab

Indexed keywords

RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; EYE TUMOR; FEMALE; LYMPHOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VITREOUS BODY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AQUEOUS HUMOR; EYE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HALF-LIFE; INJECTIONS; LYMPHOMA, B-CELL; MALE; MODELS, BIOLOGICAL; RABBITS; VITREOUS BODY;

EID: 31644446964     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2005.09.018     Document Type: Article

References (57)

1. J. Ambati, E.S. Gragoudas, J.W. Miller, T.T. You, K. Miyamoto, F.C. Delori, and A.P. Adamis Transscleral delivery of bioactive protein to the choroid and retina Invest. Ophthalmol. Vis. Sci. 41 2000 1186 1191
2. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, A. Carbonez, and P. Rutgeerts Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N. Engl. J. Med. 348 2003 601 608
3. C.C. Barr, W.R. Green, J.W. Payne, D.L. Knox, A.D. Jensen, and R.L. Thompson Intraocular reticulum-cell sarcoma: clinico-pathologic study of four cases and review of the literature Surv. Ophthalmol. 19 1975 224 239
4. B. Bataille, V. Delwail, E. Menet, P. Vandermarcq, P. Ingrand, M. Wager, G. Guy, and F. Lapierre Primary intracerebral malignant lymphoma: report of 248 cases J. Neurosurg. 92 2000 261 266
5. A. Bill The albumin exchange in the rabbit eye Acta Physiol. Scand. 60 1964 18 29
6. A. Bill, G. Sperber, and K. Ujiie Physiology of the choroidal vascular bed Int. Ophthalmol. 6 1983 101 107
7. R.A. Bush, B. Lei, W. Tao, D. Raz, C.C. Chan, T.A. Cox, M. Santos-Muffley, and P.A. Sieving Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology Invest. Ophthalmol. Vis. Sci. 45 2004 2420 2430
8. P.M. Cardarelli, M. Quinn, D. Buckman, Y. Fang, D. Colcher, D.J. King, C. Bebbington, and G. Yarranton Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines Cancer Immunol. Immunother. 51 2002 15 24
9. G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood 104 2004 2635 2642
10. N. Cassoux, H. Merle-Beral, V. Leblond, B. Bodaghi, D. Milea, S. Gerber, C. Fardeau, I. Reux, K.H. Xuan, C.C. Chan, and P. LeHoang Ocular and central nervous system lymphoma: clinical features and diagnosis Ocul. Immunol. Inflamm. 8 2000 243 250
11. C.C. Chan, and D.J. Wallace Intraocular lymphoma: update on diagnosis and management Cancer Control 11 2004 285 295
12. C.C. Chan, D. Shen, J.J. Hackett, R.R. Buggage, and N. Tuaillon Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma Ophthalmology 110 2003 421 426
13. L.T. Chylack Jr, and A.R. Bellows Molecular sieving in suprachoroidal fluid formation in man Invest. Ophthalmol. Vis. Sci. 17 1978 420 427
14. L.M. DeAngelis Primary central nervous system lymphomas Curr. Treat. Options Oncol. 2 2001 309 318
15. L.M. DeAngelis Brain tumors N. Engl. J. Med. 344 2001 114 123
16. J.Y. Driot, G.D. Novack, K.D. Rittenhouse, C. Milazzo, and P.A. Pearson Ocular pharmacokinetics of fluocinolone acetonide after retisert intravitreal implantation in rabbits over a 1-year period J. Ocul. Pharmacol. Ther. 20 2004 269 275
17. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
18. B.C. Fishburne, D.J. Wilson, J.T. Rosenbaum, and E.A. Neuwelt Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma Arch. Ophthalmol. 115 1997 1152 1156
19. J. Gaudreault, W. Webb, and M. van Hoy Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits AAPS Pharm. Sci. Suppl. 1 1999 3207
20. G.R. Gaul, and R.F. Brubaker Measurement of aqueous flow in rabbits with corneal and vitreous depots of fluorescent dye Invest. Ophthalmol. Vis. Sci. 27 1986 1331 1335
21. A. Harjunpaa, T. Wiklund, J. Collan, R. Janes, J. Rosenberg, D. Lee, A. Grillo-Lopez, and S. Meri Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma Leuk. Lymphoma 42 2001 731 738
22. J.S. Heier Review of LucentisTM (Ranibizumab, RhuFab V2) Phase I/II Trial Results: 6-Month Treatment of Exudative AMD, ARVO, Fort Lauderdale, Florida 2004 pp. Poster 1109
23. F.H. Hochberg, and D.C. Miller Primary central nervous system lymphoma J. Neurosurg. 68 1988 835 853
24. H. Kazkaz, and D. Isenberg Anti B cell therapy (rituximab) in the treatment of autoimmune diseases Curr. Opin. Pharmacol. 4 2004 398 402
25. I.C. Kuo, A. Rechdouni, N.A. Rao, R.H. Johnston, T.P. Margolis, and E.T. Cunningham Jr Subretinal fibrosis in patients with vogt-koyanagi-harada disease Ophthalmology 107 2000 1721 1728
26. W.K. Lim, S.P. Chee, I. Sng, R.B. Nussenblatt, and C.C. Chan Immunopathology of progressive subretinal fibrosis: a variant of sympathetic ophthalmia Am. J. Ophthalmol. 138 2004 475 477
27. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, L.J. Arend, J.A. Sloand, J. Rosenblatt, and I. Sanz B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum. 50 2004 2580 2589
28. E.A. Maher, and H.A. Fine Primary CNS lymphoma Semin. Oncol. 26 1999 346 356
29. D.G. Maloney Concepts in radiotherapy and immunotherapy: anti-bCD20 mechanisms of acton and targets Semin. Oncol. 32 Suppl. 1 2005 19 26
30. D.M. Maurice Flow of water between aqueous and vitreous compartments in the rabbit eye Am. J. Physiol. 252 1987 F104 F108
31. P.J. Missel Hydraulic flow and vascular clearance influences on intravitreal drug delivery Pharm. Res. 19 2002 1636 1647
32. J. Mordenti, K. Thomsen, V. Licko, L. Berleau, J.W. Kahn, R.A. Cuthbertson, E.T. Duenas, A.M. Ryan, C. Schofield, T.W. Berger, Y.G. Meng, and J. Cleland Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation Toxicol. Sci. 52 1999 101 106
33. J. Mordenti, R.A. Cuthbertson, N. Ferrara, K. Thomsen, L. Berleau, V. Licko, P.C. Allen, C.R. Valverde, Y.G. Meng, D.T. Fei, K.M. Fourre, and A.M. Ryan Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol. Pathol. 27 1999 536 544
34. S. Nasir, and L.M. DeAngelis Update on the management of primary CNS lymphoma Oncology (Huntingt) 14 2000 228 234 (discussion 237-42, 244)
35. E.A. Neuwelt, P.A. Barnett, C.I. McCormick, E.P. Frenkel, and J.D. Minna Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain Neurosurgery 17 1985 419 423
36. A.G. Palestine, R.B. Nussenblatt, C.C. Chan, J.J. Hooks, L. Friedman, and T. Kuwabara Histopathology of the subretinal fibrosis and uveitis syndrome Ophthalmology 92 1985 838 844
37. W. Paulus Classification, pathogenesis and molecular pathology of primary CNS lymphomas J. Neurooncol. 43 1999 203 208
38. P.A. Pearson, G.J. Jaffe, D.F. Martin, G.J. Cordahi, H. Grossniklaus, E.T. Schmeisser, and P. Ashton Evaluation of a delivery system providing long-term release of cyclosporine Arch. Ophthalmol. 114 1996 311 317
39. R.L. Peiffer, L. Pohm-Thorsen, and K. Corcoran Models in ophthalmology and vision research P.J. Manning D.H. Ringler C.E. Newcomer The Biology of the Laboratory Rabbit 1994 Academic Press San Diego 409 433
40. H. Pels, H. Schulz, O. Manzke, E. Hom, A. Thall, and A. Engert Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab J. Neurooncol. 59 2002 213 216
41. H. Pels, H. Schulz, U. Schlegel, and A. Engert Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature Onkologie 26 2003 351 354
42. G.A. Peyman, and D. Bok Peroxidase diffusion in the normal and laser-coagulated primate retina Invest. Ophthalmol. 11 1972 35 45
43. R.L. Radius, and D.R. Anderson Distribution of albumin in the normal monkey eye as revealed by Evans blue fluorescence microscopy Invest. Ophthalmol. Vis. Sci. 19 1980 238 243
44. J.J. Raizer, L.M. DeAngelis, A.D. Zelenetz, and L.E. Abrey Activity of rituximab in primary central nervous system lymphoma Proc. ASCO 19 2000 (abstract 642)
45. T.W. Ruhstaller, U. Amsler, and T. Cerny Rituximab: active treatment of central nervous system involvement by non-hodgkin's lymphoma? Ann. Oncol. 11 2000 374 375
46. R.H. Schindler, D. Chandler, R. Thresher, and R. Machemer The clearance of intravitreal triamcinolone acetonide Am. J. Ophthalmol. 93 1982 415 417
47. P.A. Sieving, R.C. Caruso, W. Tao, D.J.S. Thompson, K.R. Fullmer, H. Rodriguez-Coleman, and R.A. Bush Phase I Study of Ciliary Neurotrophic Factor (CNF) Delivered by Intravitreal Implant of Encapsulated Cell Technology (ECT) Device in Patients With Retinitis Pigmentosa, ARVO, Fort Lauderdale, Florida 2005
48. J.R. Smith, J.T. Rosenbaum, D.J. Wilson, N.D. Doolittle, T. Siegal, E.A. Neuwelt, and J. Pe'er Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement Ophthalmology 109 2002 1709 1716
49. J.R. Smith, R.M. Braziel, S. Paoletti, M. Lipp, M. Uguccioni, and J.T. Rosenbaum Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma Blood 101 2003 815 821
50. M.S. Stay, J. Xu, T.W. Randolph, and V.H. Barocas Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor Pharm. Res. 20 2003 96 102
51. G. Velez, M.D. de Smet, S.M. Whitcup, M. Robinson, R.B. Nussenblatt, and C.C. Chan Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature Surv. Ophthalmol. 44 2000 518 526
52. G. Velez, C.C. Chan, and K.G. Csaky Fluorescein angiographic findings in primary intraocular lymphoma Retina 22 2002 37 43
53. G. Velez, H.C. Boldt, S.M. Whitcup, R.B. Nussenblatt, and M.R. Robinson Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma Ophthal. Surg. Lasers 33 2002 329 333
54. L. Virgolini, and V. Marzocchi Rituximab in autoimmune diseases Biomed. Pharmacother. 58 2004 299 309
55. S.M. Whitcup, M.D. de Smet, B.I. Rubin, A.G. Palestine, D.F. Martin, M. Burnier Jr., C.C. Chan, and R.B. Nussenblatt Intraocular lymphoma. Clinical and histopathologic diagnosis Ophthalmology 100 1993 1399 1406
56. N. Worakul, and J.R. Robinson Review: ocular pharmacokinetics/ pharmacodynamics Eur. J. Pharm. Biopharm. 44 1997 71 83
57. N. Zhang, L.A. Khawli, P. Hu, and A.L. Epstein Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-hodgkin's lymphomas Clin. Cancer Res. 11 2005 5971 5980